Aerobic glycolysis: a novel target in kidney cancer

Для перевода нажмите


Brian Shuch et al. Expert Review of Anticancer Therapy, June 2013, Vol. 13, No. 6, Pages 711-719


Renal cell carcinoma (RCC) is a heterogenous group of cancers that arise from the nephron. While there are distinct histologic subtypes associated with common genetic alterations, most forms of RCC are linked by a common pathway of dysregulated metabolism. Reliance on aerobic glycolysis, a feature of cancer first hypothesized by Warburg, is a common feature in sporadic and hereditary forms of kidney cancer. Two hereditary forms of RCC, succinate dehydrogenase (SDH) and hereditary leiomyomatosis and RCC (HLRCC), are characterized by mutations in Krebs cycle enzymes, rendering them dependent on glycolysis for energy requirements. The reliance on these pathways may make them vulnerable to novel metabolic strategies, including inhibition of glycolysis, glucose uptake and macromolecule biosynthesis.

Aerobic glycolysis  a novel target in kidney cancer 1

Figure 1. Macromolecule generation using glutamine as a biologic precursor.

Aerobic glycolysis  a novel target in kidney cancer 2

Figure 2. Proposed mechanisms of tumorigenesis in hereditary leiomyomatosis renal cell carcinoma. Due to loss of function of fumarate hydratase, fumarate accumulates, inhibiting HPHs. Inactivation of HPH leads to intracellular HIF accumulation and transcription of important mediators of angiogenesis, growth and proliferation. In addition, upregulation of fumarate can lead to post-translational modification (succination of cysteine residues) and inactivation of KEAP1. This results in NRF2 dysregulation and transcriptional activation of several NRF2-dependant genes that mediate the cellular antioxidant response. Both HIF and NRF2 contribute to the aberrant metabolic signature associated with FH inactivation.C: Cysteine residue; FH: Fumarate hydratase; HIF: Hypoxia-inducible factor; HPH: HIF prolyl hydroxylase; NRF: Nuclear factor; S: Succination of the cysteine residues.

Aerobic glycolysis  a novel target in kidney cancer 3

Figure 3. Metabolic flow of glucose and opportunities for therapeutic intervention in cancer. LDH: Lactate dehydrogenase.

Renal cell carcinoma (RCC) accounts for approximately 95% of neoplasms arising from the kidney. Despite the availability of several new agents for the treatment of advanced kidney cancer since late 2005, mortality from kidney cancer remains fairly stable [1]. With the exception of high-dose IL-2, agents used to treat advanced kidney cancer are not curative and seldom lead to long-term durable responses. This underscores the need to continue the search for new and effective RCC therapies.

While once considered a single disease, several histologic subtypes of kidney cancer characterized by classic morphologic features have been established. Individual subtypes of kidney cancer are characterized by distinct genetic alterations and metabolic properties, and therefore one therapy is not likely to be effective for all tumor types. With improved understanding of the unique biology of clear cell RCC (ccRCC; VHL inactivation), agents targeting key components of the VHL–hypoxia-inducible factor (HIF)–VEGF axis have been developed and form the mainstay of therapy against this subtype of kidney cancer [2]. Applying this strategy in patients with non-ccRCC is not supported by similar biologic rationale, and at this time, the clinical benefit of VEGF-targeted therapy in these cancers appears to be modest [3]. Recent insights into the biology of kidney cancer suggest that dysregulated metabolic pathways play an important role in many subtypes of this disease [4]. An improved understanding of the metabolic changes underlying different forms of kidney cancer is likely to lead to innovative therapeutic strategies for the management of this disease.

Aerobic glycolysis in cancer                     

Warburg effect

Glycolysis is a multistep process where glucose is converted to pyruvate. Most differentiated human tissues oxidize pyruvate to acetyl-CoA by pyruvate dehydrogenase (PDH) for entry into the mitochondrial Krebs cycle, the primary means of energy (ATP) production via oxidative phosphorylation. In the absence of oxygen, cells are able to generate ATP, albeit less efficiently, by converting pyruvate into lactate by the enzyme lactate dehydrogenase (LDH). In the early half of the 20th century, Otto Warburg first noted that, compared with normal cells, cancer cells consumed large amounts of glucose and produced lactate even in the presence of oxygen (aerobic glycolysis). This phenomenon was named the ‘Warburg effect’ and was hypothesized to be caused by mitochondrial dysfunction, thereby rendering the cells deficient in oxidative phosphorylation and dependent on aerobic glycolysis for generation of ATP [5]. During his Nobel Laureate Meeting Lecture in 1966, Warburg concluded that “the prime cause of cancer is the replacement of the respiration of oxygen in normal body cells by a fermentation of sugar” [6]. The validity of this theory has been much debated over the past several decades, and while several lines of evidence suggest that tumors do indeed preferentially use aerobic glycolysis, support for a concomitant or causative defect in mitochondrial function is lacking in all but a few models [7].

Critics of the Warburg effect initially argued that glycolytic shift in cancer resulted from tumor hypoxia, with a consequent switch to anaerobic glycolysis and enhanced lactate production. As solid tumors frequently outgrow their oxygen supply, anaerobic glycolysis is a common occurrence. Induction of HIF acts to restore oxygen balance by induction of glycolysis, erythropoiesis and stimulation of angiogenesis [8,9]. Whether tumor glycolysis happened independently of hypoxia (the Warburg effect) was a big question. Over the last few years, interest in this theory has been rekindled by evidence suggesting that oncogene activation or loss of tumor suppressor function could lead to a metabolic shift toward aerobic glycolysis [10–12].

Role of HIF in glycolysis

Several cancers are associated with HIF overexpression despite normoxia. HIF1-α is believed to play a key role in the induction of glycolysis, and stabilization of this protein either due to hypoxia or oncogenic alterations can promote glycolysis [13]. In clear cell kidney cancer, VHL alteration by mutation or hypermethylation inhibits ubiquitination and subsequent proteosomal degradation of HIFα subunits [9,14–17]. Other mechanisms of normoxic HIF stabilization include ras activation, accumulation of Krebs cycles substrates such as fumarate and activation of the PI3K/AKT/mTOR pathway [18]. While HIF expression plays an important role in the regulation of glycolysis, there are multiple mediators of this process. Mechanisms of HIF-independent aerobic glycolysis have been demonstrated in cancer, and were first linked to activation of c-Myc [12]. Overexpression of c-Myc results in increased expression of several genes that promote glycolysis such as LDH-A, PKM2, GLUT1 and hexokinase 2 [12,19,20]. Other alterations in oncogenenic pathways such as PI3K/AKT/mTOR also appear to be key mediators of a glycolytic switch in cancer [10].

Aerobic glycolysis & macromolecule generation

Cells require a constant pool of macromolecules such as proteins, lipids and nucleotides to support growth and proliferation. Cells with a high proliferative rate, such as tumor cells, acquire many alterations that help satisfy their exaggerated metabolic needs. Glucose and glutamine are the major source of carbon and nitrogen molecules necessary for macromolecule synthesis. Aerobic glycolysis, by engendering a high glucose flux into cells, may help provide an abundant supply of the necessary substrates for macromolecule synthesis. Krebs cycle components such as citrate are important intermediaries in the synthesis of macromolecules from glucose and glutamine. In cells where entry of glucose into the Krebs cycle is limited (as with inactivation of key Krebs cycle enzymes such as fumarate hydratase [FH]), glutamine, by a process known as glutaminolysis, serves as the major source of biosynthetic intermediaries (Figure 1). Approaches aimed at targeting tumor glutaminolysis are being actively explored and may complement strategies designed to interfere with glycolysis.

What drives aerobic glycolysis in kidney cancer                            

Interruption of the Krebs cycle

At least two forms of hereditary kidney cancer appear to arise as a result of germline-inactivating mutations in genes encoding Krebs cycle enzymes. The resulting incapacitation of the Krebs cycle forces the cells to use glycolysis as the major source of energy production. While these provide perhaps the best examples of the Warburg effect in human cancer, other tumors, including sporadically occurring renal tumors, may have similar metabolic dysfunction (e.g., mutations in isocitrate dehydrogenase in CNS tumors and leukemias). Mitochondrial mutations in complex I have also been described in oncocytoma, the most common benign renal tumor [21]. In addition, somatic alterations in mitochondrial genes have also been reported in RCC [22,23].

Hereditary leiomyomatosis RCC

Hereditary leiomyomatosis and RCC (HLRCC) is an autosomal-dominant condition characterized by the development of cutaneous and uterine leiomyomas and kidney cancer [24–28]. Germline-inactivating mutations in FH are responsible for HLRCC [29]. This key enzyme is responsible for the conversion of fumarate to malate in the Krebs cycle. Loss of FH activity leads to impairment of oxidative phosphorylation and reliance on aerobic glycolysis to meet the bioenergetic needs of the cell [30]. Approximately 15–30% of individuals affected with HLRCC develop kidney cancer that is a clinically aggressive papillary variant with large orangiophilic nuclei and a characteristic perinucelar halo [26,28,31].

Succinate dehydrogenase deficiency

Hereditary paraganglioma is a syndrome manifested by head and neck paraganglioma and pheochromocytoma. Germline alterations in genes that encode the subunits of succinate dehydrogenase (SDH), are associated with this entity [32–34]. SDH, an enzyme located on the inner mitochondrial membrane, consists of succinate dehydrogenase (SDH)A, SDHB, SDHC and SDHD subunits. SDH catalyzes the oxidation of succinate to fumarate in the Krebs cycle and serves as complex II in the electron-transport chain. The identification of germline mutations in SDHB in familial kidney cancer patients led to the realization that RCC is another disease manifestation [35,36]. Renal tumors associated with this syndrome demonstrate impaired oxidative phosphorylation with reliance on aerobic glycolysis and are clinically aggressive [37,38]. Tumors associated with SDHB appear to have a distinct morphology with cuboidal cells having ‘bubbly, eosinophilic cytoplasm’ with indistinct cell borders [39].

Upregulation of HIF

Inactivating mutations in VHL and upregulation of HIF are the hallmark of both sporadic and hereditary ccRCC [14,16,17]. Increased intracellular HIF, particularly HIF1-α, leads to transcriptional upregulation of a variety of genes, including several – GLUT1, PFK2, PDH, LDH-A – that promote aerobic glycolysis. HIF1-α can also be upregulated by VHL-independent mechanisms. Tumors associated with HLRCC and those resulting from SDH mutations express high levels of HIF1-α [40,41]. In patients with HLRCC, biallelic inactivation of FH leads to accumulation of fumarate. Similarly, in cancers associated with SDH mutations, intracellular levels of succinate accumulate. Both fumarate and succinate appear to interfere with the hydroxylation of HIF by HIF prolyl hydroxylases, leading to intracellular HIF accumulation (Figure 2).

HIF can also be upregulated by activation of the mTOR pathway. mTOR is a key regulator of cell growth and proliferation, and is commonly upregulated in many cancers. In ccRCC, mutations in an upstream regulator of mTOR function (PTEN) are infrequently observed [42,43]. Decreased expression of PTEN in the absence of a discernible mutation is common and is believed to contribute to an activated downstream AKT/mTOR pathway [42,44]. Mutations in TSC1 and TSC2 can also upregulate mTOR and have been associated with renal angiomyolipomas and kidney cancer. The mTOR pathway is also activated in tumors associated with Birt–Hogg–Dubé syndrome, a hereditary kidney cancer syndrome resulting from germline inactivating mutations in folliculin and characterized by bilateral multifocal renal tumors of varied histology [45,46].

Reactive oxygen species

Reactive oxygen species (ROS) are oxygen free radicals characterized by unpaired electrons. These highly reactive molecules are byproducts of normal oxidative metabolism and function in normal homeostasis and signaling. However, with increased levels of ROS, cellular damage and dysfunctional signaling can ensue. In HLRCC, increased cellular glucose levels stimulate NADPH-mediated ROS production [47]. The increased levels of ROS can directly stabilize HIF1, contributing to a metabolic shift toward aerobic glycolysis [48,49]. In HLRCC, ROS are believed to stabilize HIF1 by direct inhibition of HIF prolyl hydroxylases [47].

In SDH, increased levels of ROS may contribute to HIF1 stabilization and tumorigenesis [50]. In yeast models, loss of SDH function generates increased levels ROS and the accumulation of oxidized proteins [51]. However, data from SDH knockdown models in mammalian cells demonstrate that increased levels of ROS do not occur [41].

NRF2/KEAP1

Although HIF is upregulated in both VHL null and FH-deficient kidney cancer, these two entities demonstrate significant histological and clinical differences. In a bid to account for these differences, several groups have investigated the role of HIF-independent pathways in FH-associated renal tumors. Animal models attempting to recapitulate HLRCC have been developed using conditional FH(-/-) knockout mice, which develop large renal cysts and renal failure [52]. Crossing these mice with HIF1 or HIF2 knockout mice fails to ameliorate this renal phenotype, suggesting that in this model, the renal abnormalities associated with FH loss are independent of HIF1 and HIF2 [53]. Analyses of renal cysts from these FH-/- mice demonstrate an aberrant antioxidant response pathway that may contribute to HLRCC-associated renal tumorigenesis. At least two groups investigating the mechanism by which FH loss leads to upregulation of antioxidant genes have demonstrated that elevated intracellular fumarate leads to post-translational modification of KEAP1. KEAP1 is a regulator of NRF2, a master transcriptional regulator of the response pathway to oxidative stress. Under normal conditions, KEAP1 is believed to bind to and ubiquinate NRF2, resulting in its degradation. The interaction between KEAP1 and NRF2 is disrupted following succination of the former in the presence of elevated levels of fumarate, leading to intracellular accumulation of NRF2 and activation of antioxidant signaling pathways [53,54]. Recent evidence suggests that NRF2 is an important regulator in cancer cell metabolism. Mitsuishi and colleagues recently demonstrated that activation of this pathway results in the redirection of glucose and glutamine into anabolic pathways such as glycolysis and the pentose phosphate pathway [55]. In addition to HLRCC tumors, dysregulation of the KEAP1/NRF pathway has also been reported in the morphologically similar sporadic papillary type II RCC [54].

Other oncogenic pathways

The PI3K/AKT/MTOR and myc proto-oncogene pathways are activated in different subtypes of kidney cancer. Both pathways play critical roles in the altered cellular metabolism seen in kidney cancer. Myc has been shown to upregulate the expression of various proglycolytic enzymes, such as PKM2, hexokinase 2 and LDH-A. In addition, both the glucose transporter GLUT1 and the glutamine transporter ASCT2 are regulated by Myc. The AKT/mTOR pathway stimulates glycolysis directly by upregulating several key glycolytic enzymes and indirectly by translational upregulation of HIF.

Targeting aerobic glycolysis                     

A variety of rational ‘metabolic’ targets have been proposed and are being evaluated in preclinical/clinical studies. These targets include critical components of aerobic glycolysis as well as pathways involved in biosynthesis of macromolecules (Figure 3). The following discussion is restricted to those targets considered relevant to kidney cancer.

Glucose uptake

Cellular glucose uptake is regulated by transmembrane GLUT receptors. Different genes encode for GLUT isoforms, which have variable distribution based on tissue type. Cancer cells frequently upregulate GLUT expression in an attempt to increase glucose uptake, especially important for cells that rely on aerobic glycolysis. Inhibiting this process could hinder cell proliferation by ‘glucose starvation’ and make them more susceptible to cell death. This approach may be a viable option in ccRCC, as a recent study demonstrated that VHL-deficient cell lines demonstrate synthetic lethality with GLUT1 inhibition, as did cancers with obligate aerobic glycolysis – such as those associated with FH and SDH mutations [56]. Inhibitors of glucose uptake are currently in development.

PKM2

Pyruvate kinase (PK) is the last enzyme involved in glycolysis, catalyzing the dephosphorylation of phosphoenolpyruvate to pyruvate with the generation of a molecule of ATP. Several isoforms of PK have been identified and the expression of these isoforms is tissue dependent. The PKM gene has two splice variants (M1 and M2), varying by the presence of one exon [57]. The M2 isoform is present in embryonic tissues and in cells requiring rapid glucose turnover, including muscle and brain cells. This enzyme is unique in that it can exist in both dimeric and tetrameric forms [58]. In cancer tissue, PKM2 is preferentially expressed and is important to tumor metabolism and proliferation [59–61]. The ratio of the dimeric to tetrameric forms determines enzyme activity and whether phosphoenolpyruvate is converted to pyruvate or is shuttled into biosynthesis of other molecules such as amino acids and nucleic acids [62].

PKM2 is being explored as a therapeutic target in cancer cells dependent on aerobic glycolysis. Knockdown of PKM2 decreases in vitro cell proliferation and glucose metabolism, and also inhibits growth of xenografts [63]. Small-molecule inhibitors targeting PKM2 are currently under development [64].

Hexokinase

Hexokinase is the first enzyme involved in the glycolytic pathway and catalyzes the phosphorylation of glucose into glucose-6-phosphate. Once phosphorylated, glucose-6-phosphate cannot exit the cell. 2-deoxy-d-glucose (2DG) is a glucose analog that is taken up by cells via the same mechanisms mediating glucose uptake. Once in the cell, 2DG is phosphorylated by hexokinase. However, after this step, the resultant metabolite cannot be processed by glucose-6-phosphate isomerase, the second enzyme in glycolysis. Accumulation of phosphorylated 2DG leads to inhibition of hexokinase. Treatment with 2DG has long been known to inhibit in vitro tumor growth [65]. 2DG inhibits in vitro growth of UOK262, an FH-deficient kidney cancer cell line derived from a patient with HLRCC. The agent has been evaluated in Phase I and II studies. A case report of a patient with metastatic HLRCC treated with 2DG was recently reported; unfortunately, the patient did not appear to derive any clinical benefit [66]. Treatment with 2DG may not be effective as monotherapy, as escape mechanisms such as activation of the PI3K/AKT pathway may overcome inhibition of hexokinase [67]. Other pharmacologic mechanisms aimed at inhibiting hexokinase have been explored. Inhibitors such as 3-bromopyruvate and lonidamine can inhibit hexokinase function and may be a useful strategy for tumors relying on aerobic glycolysis [68]. Lonidamine was in clinical development in the USA, but these trials were terminated due to modest clinical activity. However, this drug was approved in Italy for cancer therapy over 20 years ago [68].

LDH-A

LDH catalyzes the reversible conversion of lactate to pyruvate. LDH exists in two major isoforms; LDH-A is the isoform that promotes conversion of pyruvate into lactate. As LDH-A is upregulated in solid tumors reliant on glycolysis, inhibition of this enzyme may be a valid therapeutic approach [69]. Knockdown experiments in several models demonstrate decreased in vitro cell proliferation and in vivo tumorigenicity [69]. HLRCC-associated tumors appear to overexpress LDH-A, and knock-down of this enzyme in UOK262 limits in vitro cell proliferation and in vivo growth inhibition [70].

Hemoxygenase

Several Krebs cycle intermediates are needed for macromolecule biosynthesis, and integrity of this cycle is essential for sufficient NADH production. In cells with Krebs cycle dysfunction, the mechanisms used to generate macromolecules and NADH are not well understood. Cells dependent on aerobic glycolysis are thought to rely on high levels of glutamine metabolism for these biochemical precursors [71]. Experimental modeling and 13C labeling in mouse FH-deficient kidney cells determined that these cells utilize an alterative metabolic pathway involving heme biosynthesis and degradation for NADH production. Knockout of heme oxygenase 1, required for heme degradation, disrupts this pathway and is associated with synthetic lethality in FH-negative cells and is being explored as a therapeutic target [72].

Glutaminase

In addition to their reliance on aerobic glycolysis, cancer cells also demonstrate increased glutamine uptake, which serves as the major source of nitrogen for protein and lipid biosynthesis [71,73]. Interfering with glutamine metabolism may therefore starve the cancer cell of the necessary biosynthetic molecules required for continued growth and proliferation. Cells relying on a high rate of aerobic glycolysis are profoundly sensitive to glutamine withdrawal [74]. Therapeutic strategies aimed at blocking glutamine metabolism by glutaminase inhibition are being explored. Small-molecule inhibitors of this enzyme have been shown to block oncogenic transformation in several cell lines without affecting normal cells [75]. In glioma cell lines with a mutated Krebs cycle enzyme (isocitrate dehydrogenase), genetic and pharmacologic inhibition of glutaminase can decrease cell proliferation [76]. While this may be a promising strategy for targeting cancer metabolism, emerging data suggest that cells adapt to overcome glutaminase inhibition by activating alternative pathways for generating substrates for macromolecule synthesis. Further studies are required to determine the role of glutaminase inhibition in the treatment of cancer [77].

PDH kinase

PDH is a mitochondrial enzyme complex responsible for the decarboxylation and acetylation of pyruvate into acetyl-CoA, the starting point of the Krebs cycle. This complex is tightly regulated by two distinct enzymes, PDH phosphatase and PDH kinase. Phosphorylation of PDH inactivates the complex and shunts pyruvate toward lactate production in the cytoplasm. Methods aimed at inhibiting PDH kinase are thought to shift metabolism toward the Krebs cycle. Sodium dichloroacetate is a pyruvate analog that promotes entry of pyruvate into the Krebs cycle and has been extensively studied for cancer treatment. Cells with defects in the electron transport chain appear to be more sensitive than cells less reliant on glycolysis [68]. The agent is in early clinical trials and appears to be well tolerated.

Angiogenesis inhibitors

Prior to 2005, immunotherapy was the sole systemic modality available to patients with advanced kidney cancer. Unfortunately, only a small proportion of patients with ccRCC appear to benefit from immunotherapy, while non-ccRCC are generally not responsive [78,79]. Newer agents targeting the VEGF or mTOR pathways show only modest activity in papillary RCC [80]. Thus, no effective strategy exists for papillary variants of RCC. In a Phase II study of erlotinib in papillary RCC, a low overall response rate was observed, although the median survival of 27 months was encouraging [81].

The authors hypothesized that combining a VEGF pathway antagonist and an EGFR inhibitor would constrain glucose delivery to tumor cells by targeting its vasculature; targeting a growth factor pathway downstream from HIF would theoretically act in concert with the antiangiogenic approach. This approach was first evaluated in ccRCC using using bevacizumab and erlotinib therapy, a combination that was well tolerated [82]. This approach is currently being evaluated in patients with papillary RCC in a Phase II trial at the National Cancer Institute (trial ID: NCI01130519).

Conclusion                       

A variety of kidney cancer subtypes are characterized by dysregulated metabolic pathways. The dependence of some tumors on aerobic glycolysis is an Achilles’ heel that can be exploited in targeted therapeutic strategies. Multiple steps in the glycolytic pathway have been evaluated as possible anticancer targets in preclinical studies, and some agents have entered early clinical trials for solid tumors. It is hoped that these approaches will spawn novel therapeutic options in the fight against kidney cancer.

Expert commentary                     

Despite the availability of several new agents for the treatment of kidney cancer, most patients with advanced disease die from it. With the exception of high-dose IL-2, the current agents used to treat advanced kidney cancer are not curative and seldom lead to durable responses. An improved understanding of the genetic basis of kidney cancer has led to the belief that this cancer is fundamentally a disease characterized by metabolic alterations. Targeting metabolic dysregulation, including the reliance on aerobic glycolysis, is a promising research avenue and may lead to the development of more effective forms of therapy.

Five-year view                

While kidney cancer is a heterogenous group of diseases, they are characterized by metabolic dysregulation due to mutations in genes involved in the cells’ ability to sense oxygen, iron, nutrients or energy. Reliance on aerobic glycolysis is the hallmark of two hereditary forms of kidney cancer, HLRCC and SDH. In addition, aerobic glycolysis is also seen in other forms of kidney cancer including ccRCC. Targeting aerobic glycolysis and other aberrant metabolic pathways in kidney cancer is being evaluated in preclinical/clinical studies. In the next few years, we expect these therapeutic strategies to enter early-phase clinical trials for both hereditary and sporadic forms of kidney cancer. Some promising metabolic strategies include blocking cellular glucose uptake, inhibition of critical glycolytic enzymes (hexokinase, PK and LDH) and targeting glutamine metabolism, a major source of nitrogen for protein and lipid biosynthesis.

References                       

  1. American Cancer Society. Cancer Facts & Figures 2010. American Cancer Society, GA, USA (2010).
  2. Linehan WM. Molecular targeting of VHL gene pathway in clear cell kidney cancer. J. Urol. 170,593(2003).
  3. Singer EA, Bratslavsky G, Linehan WM, Srinivasan R. Targeted therapies for non-clear renal cell carcinoma. Target. Oncol.5(2),119–129(2010).
  4. Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat. Rev. Urol.7(5),277–285(2010).
  5. Warburg O. On respiratory impairment in cancer cells. Science124(3215),269–270(1956).
  6. Warburg O. The prime cause and prevention of cancer. Presented at: the 17th Annual Lindau Nobel Laureate Meetings. Lindau, Germany(1967).
  7. Garber K. Energy boost: the Warburg effect returns in a new theory of cancer. J. Natl Cancer Inst.96(24),1805–1806(2004).
  8. Carmeliet P, Dor Y, Herbert JM et al. Role of HIF1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature394(6692),485–490(1998).
  9. Maxwell PH, Dachs GU, Gleadle JM et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl Acad. Sci. USA94(15),8104–8109(1997).
  10. Elstrom RL, Bauer DE, Buzzai M et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res.64(11),3892–3899(2004).
  11. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab.3(3),177–185(2006).
  12. Shim H, Dolde C, Lewis BC et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc. Natl Acad. Sci. USA94(13),6658–6663(1997).
  13. Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC. Differential roles of hypoxia-inducible factor 1α (HIF1α) and HIF-2α in hypoxic gene regulation. Mol. Cell. Biol.23(24),9361–9374(2003).
  14. Gnarra JR, Tory K, Weng Y et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet.7(1),85–90(1994).
  15. Herman JG, Latif F, Weng Y et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl Acad. Sci. USA91(21),9700–9704(1994).
  16. Latif F, Tory K, Gnarra J et al. Identification of the von Hippel–Lindau disease tumor suppressor gene. Science260(5112),1317–1320(1993).
  17. Maxwell PH, Wiesener MS, Chang GW et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature399(6733),271–275(1999).
  18. Chen C, Pore N, Behrooz A et al. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J. biol. chem.276,9519(2001).
  19. Kim JW, Zeller KI, Wang Y et al. Evaluation of myc E-box phylogenetic footprints in glycolytic genes by chromatin immunoprecipitation assays. Mol. Cell. Biol.24(13),5923–5936(2004).
  20. Osthus RC, Shim H, Kim S et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J. Biol. Chem.275(29),21797–21800(2000).
  21. Mayr JA, Meierhofer D, Zimmermann F et al. Loss of complex I due to mitochondrial DNA mutations in renal oncocytoma. Clin. Cancer Res.14(8),2270–2275(2008).
  22. Selvanayagam P, Rajaraman S. Detection of mitochondrial genome depletion by a novel cDNA in renal cell carcinoma. Lab. Invest.74(3),592–599(1996).
  23. Horton TM, Petros JA, Heddi A et al. Novel mitochondrial DNA deletion found in a renal cell carcinoma. Genes Chromosomes Cancer15(2),95–101(1996).
  24. Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin. Cancer Res.15(21),6479–6483(2009).
  25. Lehtonen HJ, Kiuru M, Ylisaukko-Oja SK et al. Increased risk of cancer in patients with fumarate hydratase germline mutation. J. Med. Genet.43(6),523–526(2006).
  26. Merino MJ, Torres-Cabala C, Pinto P, Linehan WM. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am. J. Surg. Pathol.31(10),1578–1585(2007).
  27. Reed WB, Walker R, Horowitz R. Cutaneous leiomyomata with uterine leiomyomata. Acta Derm. Venereol.53(5),409–416(1973).
  28. Launonen V, Vierimaa O, Kiuru M et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc. Natl Acad. Sci. USA98(6),3387–3392(2001).
  29. Alam NA, Bevan S, Churchman M et al. Localization of a gene (MCUL1) for multiple cutaneous leiomyomata and uterine fibroids to chromosome 1q42.3-q43. Am. J. Hum. Genet.68(5),1264–1269(2001).
  30. Tong WH, Sourbier C, Kovtunovych G et al. The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. Cancer Cell20(3),315–327(2011).
  31. Grubb RL 3rd, Franks ME, Toro J et al. Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J. Urol.177,2074(2007).
  32. Astuti D, Latif F, Dallol A et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am. J. Hum. Genet.69(1),49–54(2001).
  33. Baysal BE, Ferrell RE, Willett-Brozick JE et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science287(5454),848–851(2000).
  34. Niemann S, Müller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat. Genet.26(3),268–270(2000).
  35. Ricketts C, Woodward ER, Killick P et al. Germline SDHB mutations and familial renal cell carcinoma. J. Natl Cancer Inst.100(17),1260–1262(2008).
  36. Vanharanta S, Buchta M, McWhinney SR et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am. J. Hum. Genet.74(1),153–159(2004).
  37. Bratslavsky G, Linehan WM. Long-term management of bilateral, multifocal, recurrent renal carcinoma. Nat. Rev. Urol.7(5),267–275(2010).
  38. Ricketts CJ, Shuch B, Vocke CD et al. Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J. Urol.188(6),2063–2071(2012).
  39. Gill AJ, Pachter NS, Chou A et al. Renal tumors associated with germline SDHB mutation show distinctive morphology. Am. J. Surg. Pathol.35(10),1578–1585(2011).
  40. Isaacs JS, Jung YJ, Mole DR et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell8(2),143–153(2005).
  41. Selak MA, Armour SM, MacKenzie ED et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer Cell7(1),77–85(2005).
  42. Abou Youssif T, Fahmy MA, Koumakpayi IH et al. The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases. Cancer117(2),290–300(2011).
  43. Hara S, Oya M, Mizuno R, Horiguchi A, Marumo K, Murai M. Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Ann. Oncol.16(6),928–933(2005).
  44. Pantuck AJ, Seligson DB, Klatte T et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer109(11),2257–2267(2007).
  45. Baba M, Hong SB, Sharma N et al. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc. Natl Acad. Sci. USA103(42),15552–15557(2006).
  46. Hasumi Y, Baba M, Ajima R et al. Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proc. Natl Acad. Sci. USA106(44),18722–18727(2009).
  47. Sudarshan S, Sourbier C, Kong HS et al. Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1α stabilization by glucose-dependent generation of reactive oxygen species. Mol. Cell. Biol.29(15),4080–4090(2009).
  48. Finley LW, Carracedo A, Lee J et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1a destabilization. Cancer Cell19(3),416–428(2011).
  49. Shi DY, Xie FZ, Zhai C, Stern JS, Liu Y, Liu SL. The role of cellular oxidative stress in regulating glycolysis energy metabolism in hepatoma cells. Mol. Cancer8,32(2009).
  50. Eng C, Kiuru M, Fernandez MJ, Aaltonen LA. A role for mitochondrial enzymes in inherited neoplasia and beyond. Nat. Rev. Cancer3(3),193–202(2003).
  51. Smith EH, Janknecht R, Maher LJ 3rd. Succinate inhibition of α-ketoglutarate-dependent enzymes in a yeast model of paraganglioma. Hum. Mol. Genet.16(24),3136–3148(2007).
  52. Pollard PJ, Spencer-Dene B, Shukla D et al. Targeted inactivation of fh1 causes proliferative renal cyst development and activation of the hypoxia pathway. Cancer Cell11(4),311–319(2007).
  53. Adam J, Hatipoglu E, O’Flaherty L et al. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell20(4),524–537(2011).
  54. Ooi A, Wong JC, Petillo D et al. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell20(4),511–523(2011).
  55. Mitsuishi Y, Taguchi K, Kawatani Y et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell22(1),66–79(2012).
  56. Chan DA, Sutphin PD, Nguyen P et al. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci. Transl. Med.3(94),94ra70(2011).
  57. Noguchi T, Inoue H, Tanaka T. The M1- and M2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing. J. Biol. Chem.261(29),13807–13812(1986).
  58. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin. Cancer Biol.15(4),300–308(2005).
  59. Christofk HR, Vander Heiden MG, Harris MH et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature452(7184),230–233(2008).
  60. Luo W, Hu H, Chang R et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell145(5),732–744(2011).
  61. Schneider J, Neu K, Grimm H, Velcovsky HG, Weisse G, Eigenbrodt E. Tumor M2-pyruvate kinase in lung cancer patients: immunohistochemical detection and disease monitoring. Anticancer Res.22(1A),311–318(2002).
  62. Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int. J. Biochem. Cell Biol.43(7),969–980(2011).
  63. Christofk HR, Vander Heiden MG, Wu N et al. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature452,181(2008).
  64. Vander Heiden MG, Christofk HR, Schuman E et al. Identification of small molecule inhibitors of pyruvate kinase M2. Biochem. Pharmacol.79(8),1118–1124(2010).
  65. Brown J. Effects of 2-deoxyglucose on carbohydrate metabolism: review of the literature and studies in the rat. Metab. Clin. Exp.11,1098–1112(1962).
  66. Yamasaki T, Tran TA, Oz OK et al. Exploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCC. Nat. Rev. Urol.8(3),165–171(2011).
  67. Zhong D, Liu X, Schafer-Hales K et al. 2-Deoxyglucose induces Akt phosphorylation via a mechanism independent of LKB1/AMP-activated protein kinase signaling activation or glycolysis inhibition. Mol. Cancer Ther.7(4),809–817(2008).
  68. Pathania D, Millard M, Neamati N. Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. Adv. Drug Deliv. Rev.61(14),1250–1275(2009).
  69. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell9(6),425–434(2006).
  70. Xie H, Valera VA, Merino MJ et al. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol. Cancer Ther.8(3),626–635(2009).
  71. DeBerardinis RJ, Mancuso A, Daikhin E et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc. Natl Acad. Sci. USA104(49),19345–19350(2007).
  72. Frezza C, Zheng L, Folger O et al. Hem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature477(7363),225–228(2011).
  73. Mullen AR, Wheaton WW, Jin ES et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature481(7381),385–388(2012).
  74. Wise DR, DeBerardinis RJ, Mancuso A et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl Acad. Sci. USA105(48),18782–18787(2008).
  75. Wang JB, Erickson JW, Fuji R et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell18(3),207–219(2010).
  76. Seltzer MJ, Bennett BD, Joshi AD et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res.70(22),8981–8987(2010).
  77. Cheng T, Sudderth J, Yang C et al. Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc. Natl Acad. Sci. USA108(21),8674–8679(2011).
  78. Upton MP, Parker RA, Youmans A et al. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J. Immunother.28,488–495(2005).
  79. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear cell histology. J. Clin. Oncol.20(9),2376–2381(2002).
  80. Plimack E, Jonasch E, Bekele B et al. Sunitinib in papillary renal cell carcinoma (pRCC): results from a single-arm Phase II study. J. Clin. Oncol.28,15s(2010).
  81. Pan C, Hussey M, Lara P et al. Encouraging survival with erlotinib in advanced papillary renal cell carcinoma (pRCC): final results from Southwest Oncology Group study 0317. J. Clin. Oncol.26, Abstract 5051 (2008).
  82. Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J. Clin. Oncol.23(31),7889–7896(2005).
0

Добавить комментарий

Войти с помощью: 

Ваш e-mail не будет опубликован. Обязательные поля помечены *